For Q2FY2026, Pharmaniaga Berhad recorded revenue of RM1.04 billion, representing a 12.3% increase from RM926.9 million recorded in the corresponding quarter of the previous financial year. Profit after tax (PAT) improved significantly to RM13 million, compared with RM4.2 million in Q2FY2025, while profit before zakat and taxation (PBT) increased to RM17.8 million from RM7.4 million previously.
For 1HFY2026, the Group recorded revenue of RM2.22 billion, up 12.0% from RM1.98 billion in the corresponding period last year. PAT increased 31.2% to RM45.2 million from RM34.5 million previously, reflecting ongoing improvement in the Group’s operating performance and financial position.
The improved performance was underpinned by higher order volumes from Government hospitals under the APPL and stronger sales to the private healthcare segment. Supported by effective inventory management and the partial repayment of borrowings generated finance cost savings of RM7 million, further strengthening the Group’s profitability during the period.
For 1HFY2026, the Manufacturing Division remained a key earnings contributor, with earnings before interest, taxation, depreciation and amortisation increasing to RM55.6 million, compared with RM50.3 million in the corresponding period last year. The improvement was supported by stronger demand for the Group’s in-house manufactured products.
The Group also declared a second interim dividend of 0.48 sen per share for the financial year ending 31 December 2026, representing 50% of profit after tax and minority interest (PATAMI).
